Clinical trials: Depressive Illness
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder
Study of NSI-189 for Major Depressive Disorder
The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80…
- Trial name
- NCT02695472
- Testing
- 80 Milligrams NSI-189, 40 Milligrams NSI-189
- Where
- 13 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depression, Anxiety, Mental Health Issue
Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety
A digital mental health intervention (BetterHelp, Mountain View, CA) provides users with access to online therapy care for treatment of depression and anxiety.
- Conditions
- Depression, Anxiety, Mental Health Issue, Mental Health Wellness 2
- Trial name
- NCT07081061
- Testing
- BetterHelp
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Teladoc Health
Respiratory Depression
Long-term Extension Study of BEMA™ Fentanyl
This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.
- Trial name
- NCT00696137
- Testing
- BEMA Fentanyl
- Volunteers
- 5 people
- Sponsor
- BioDelivery Sciences International
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction
Trifecta Research Study
This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder…
- Conditions
- PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder
- Trial name
- NCT07717866
- Testing
- Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Axial Therapeutic Research
Major Depressive Disorder
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with…
- Trial name
- NCT01312922
- Testing
- PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
- Where
- 31 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- PharmaNeuroBoost N.V.
Major Depressive Disorder
Badalona Major Depressive Disorder Database Study
A retrospective study using a data base of anonymized medical records. The purpose of the study is to examine the different therapeutic strategies for the management of patients with major depressive disorder (MDD) and suboptimal…
- Trial name
- NCT01446692
- Where
- Spain
- Volunteers
- 2,260 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
Primary Objective: To compare the efficacy and safety of DVS-233 SR versus placebo treatment in reducing the relapse rate of depressive symptoms in subjects with major depressive disorder (MDD), and to compare the percentages of…
- Trial name
- NCT00075257
- Testing
- DVS-233 SR
- Volunteers
- 603 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
- Trial name
- CTO-TNS (NCT02805881)
- Testing
- Neurolief system
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Neurolief Ltd.
Major Depressive Disorder, Bipolar 1 Disorder
Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning
This study was designed to evaluate the efficacy of the mobile application named Circadian Rhythm for Mood (CRM), which was developed to prevent recurring episodes of mood disorders (major depressive disorders, bipolar disorders…
- Conditions
- Major Depressive Disorder, Bipolar 1 Disorder, Bipolar II Disorder
- Trial name
- NCT05400785
- Testing
- Circadian Rhythms for Mood (CRM) application - Active
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Hucircadian
Depressive Disorder and Anxiety Disorders
First Study in Humans With GSK424887
This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body…
- Trial name
- NCT01059591
- Testing
- GSK424887, PET
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mild to Moderate Depression
Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.
The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation
- Trial name
- NCT02981225
- Testing
- Phytostandard® Rhodiola-Saffron
- Where
- France
- Volunteers
- 59 people
- Sponsor
- PiLeJe
Moderate Depressive Episodes (Major Depression)
Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
The researchers in this trial want to learn more about the drug Laif® 900 in preventing the return of signs and symptoms of depressions (also called relapse) in patients suffering from moderate depression episodes.
- Trial name
- NCT04315597
- Testing
- Laif® 900, BAY98-7108
- Volunteers
- 398 people
- Sponsor
- Bayer
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fed and fasted conditions.
- Trial name
- NCT00913588
- Testing
- Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.), Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
- Trial name
- NCT00775203
- Testing
- Trazodone Hydrochloride (HCl) Extended-Release Tablets
- Where
- 36 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Labopharm Inc.
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder (MDD)
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
- Trial name
- NCT06796868
- Testing
- GW117 Tablets
- Where
- 17 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Depression, Anxiety, IBS - Irritable Bowel Syndrome
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
Viome costumers are consented and recruited for this study and complete the questionnaires upon enrollment. Any participant who previously self reported depression, anxiety, or Irritable Bowel Syndrome (IBS) qualify for this…
- Trial name
- NCT04905524
- Testing
- VIOME Precision Nutrition Program
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Viome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.